GB2259013A — Neuroprotective use of CCK antagonists
Assigned to Organon Pharma UK Ltd · Expires 1993-03-03 · 33y expired
What this patent protects
Use of CCK antagonists, especially those of formulae I-IV, in the formulation of medicaments having neuroprotective activity: <IMAGE> wherein formulae I to IV are defined in (1) US 4791215; (2) EP 0167919 and EP 0284256; (3) EP 0405537 and (4) J. Med.Chem. 34, 1508-8 (199…
USPTO Abstract
Use of CCK antagonists, especially those of formulae I-IV, in the formulation of medicaments having neuroprotective activity: <IMAGE> wherein formulae I to IV are defined in (1) US 4791215; (2) EP 0167919 and EP 0284256; (3) EP 0405537 and (4) J. Med.Chem. 34, 1508-8 (1991) respectively. The compounds are particularly useful in the treatment of stroke, hypoglycaemia, cerebral palsy, cerebral ischaemia, perinatal asphyxia, epilepsy, Huntington's chorea, Alzheimer's disease, Parkinsonism, anoxia and neurotoxemia. <IMAGE>
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.